Invention Grant
- Patent Title: CD133 related to anticancer agent resistance in colon cancer and use thereof
-
Application No.: US16848273Application Date: 2020-04-14
-
Publication No.: US11639530B2Publication Date: 2023-05-02
- Inventor: Je Sang Ko , Min-Soo Kang
- Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
- Applicant Address: KR Seoul
- Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
- Current Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
- Current Assignee Address: KR Seoul
- Agency: Sughrue Mion, PLLC
- Priority: KR10-2019-0043765 20190415
- Main IPC: C12N15/113
- IPC: C12N15/113 ; C12Q1/6886 ; A61K48/00 ; A61K45/06 ; C12N5/00
Abstract:
The present invention relates to a use of CD133 involved in resistance to an EGFR-targeting agent in colon cancer. The CD133 protein may be used as a novel target protein for diagnosing and treating resistant cancer as well as general cancer.
Public/Granted literature
- US20200325545A1 CD133 RELATED TO ANTICANCER AGENT RESISTANCE IN COLON CANCER AND USE THEREOF Public/Granted day:2020-10-15
Information query
IPC分类:
